Entrada Therapeutics (NASDAQ:TRDA) Price Target Lowered to $20.00 at HC Wainwright

Entrada Therapeutics (NASDAQ:TRDA – Free Report) had its price objective reduced by HC Wainwright from $25.00 to $20.00 in a research report released on Monday morning, Benzinga reports. They currently have a buy rating on the stock. Entrada Therapeutics Stock Performance Shares of NASDAQ:TRDA opened at $12.97 on Monday. The firm has a market capitalization […]

Related Keywords

,Nasdaq ,Northern Trust Corp ,Charles Schwab Investment Management Inc ,York Mellon Corp ,Entrada Therapeutics Inc ,Nan Fung Group Holdings Ltd ,Vanguard Group Inc ,Entrada Therapeutics ,Free Report ,Get Free Report ,New York Mellon Corp ,Schwab Investment Management ,Trust Corp ,Entrada Therapeutics Daily ,Nasdaq Trda ,Trda ,Medical ,Lower Price Target ,Hc Wainwright ,